Menu Close

Vista Wealth Management Group LLC Has $878,000 Stock Position in Johnson & Johnson (NYSE:JNJ)

view original post

Vista Wealth Management Group LLC decreased its position in Johnson & Johnson (NYSE:JNJGet Rating) by 4.1% in the 1st quarter, HoldingsChannel reports. The fund owned 4,954 shares of the company’s stock after selling 212 shares during the period. Vista Wealth Management Group LLC’s holdings in Johnson & Johnson were worth $878,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Thoroughbred Financial Services LLC raised its holdings in Johnson & Johnson by 51.1% in the 1st quarter. Thoroughbred Financial Services LLC now owns 38,478 shares of the company’s stock valued at $6,819,000 after acquiring an additional 13,014 shares in the last quarter. swisspartners Ltd. raised its holdings in Johnson & Johnson by 138.5% in the 1st quarter. swisspartners Ltd. now owns 10,088 shares of the company’s stock valued at $4,825,000 after acquiring an additional 5,858 shares in the last quarter. Brio Consultants LLC bought a new stake in shares of Johnson & Johnson in the 1st quarter valued at approximately $230,000. Northeast Investment Management grew its stake in shares of Johnson & Johnson by 0.7% in the 1st quarter. Northeast Investment Management now owns 224,763 shares of the company’s stock valued at $39,835,000 after purchasing an additional 1,545 shares during the period. Finally, Gladstone Institutional Advisory LLC grew its stake in shares of Johnson & Johnson by 15.5% in the 1st quarter. Gladstone Institutional Advisory LLC now owns 56,535 shares of the company’s stock valued at $10,020,000 after purchasing an additional 7,586 shares during the period. Institutional investors and hedge funds own 68.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on JNJ shares. Morgan Stanley upped their price objective on Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a research note on Friday, July 8th. Wells Fargo & Company upped their price objective on Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a research note on Wednesday, July 13th. UBS Group lowered their price objective on Johnson & Johnson from $185.00 to $180.00 in a research note on Thursday, July 21st. Citigroup decreased their price target on Johnson & Johnson from $205.00 to $201.00 in a research report on Wednesday, July 20th. Finally, SVB Leerink decreased their price target on Johnson & Johnson from $200.00 to $194.00 in a research report on Wednesday, July 20th. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $189.89.

Insider Buying and Selling at Johnson & Johnson

In other news, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. The disclosure for this sale can be found here. Corporate insiders own 0.35% of the company’s stock.

Johnson & Johnson Stock Down 1.6 %

Shares of JNJ opened at $171.79 on Friday. The firm has a market capitalization of $451.67 billion, a price-to-earnings ratio of 25.01, a PEG ratio of 3.29 and a beta of 0.59. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.14 and a current ratio of 1.42. The business’s fifty day moving average price is $175.41 and its two-hundred day moving average price is $174.52. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. The firm had revenue of $24.02 billion for the quarter, compared to analyst estimates of $23.85 billion. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period last year, the company earned $2.48 EPS. On average, analysts predict that Johnson & Johnson will post 10.05 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be given a $1.13 dividend. The ex-dividend date of this dividend is Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a yield of 2.63%. Johnson & Johnson’s payout ratio is 65.79%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.